Showing 14,601 - 14,620 results of 29,839 for search '(( 50 ((a decrease) OR (mean decrease)) ) OR ( 5 ((step decrease) OR (nn decrease)) ))', query time: 0.85s Refine Results
  1. 14601

    Data_Sheet_1_Effects of COVID-19-targeted non-pharmaceutical interventions on pediatric hospital admissions in North Italian hospitals, 2017 to 2022: a quasi-experimental study int... by Giuseppe Maglietta (12992976)

    Published 2024
    “…Level change for Mental Disorders significantly decreased during school closure (HRR 0.50, 95%CI 0.30–0.82) but increased during mitigation measures by 28% (HRR 1.28, 95%CI 0.98–1.69).…”
  2. 14602

    Data_Sheet_1_Effects of COVID-19-targeted non-pharmaceutical interventions on pediatric hospital admissions in North Italian hospitals, 2017 to 2022: a quasi-experimental study int... by Giuseppe Maglietta (12992976)

    Published 2024
    “…Level change for Mental Disorders significantly decreased during school closure (HRR 0.50, 95%CI 0.30–0.82) but increased during mitigation measures by 28% (HRR 1.28, 95%CI 0.98–1.69).…”
  3. 14603

    Data_Sheet_1_Effects of COVID-19-targeted non-pharmaceutical interventions on pediatric hospital admissions in North Italian hospitals, 2017 to 2022: a quasi-experimental study int... by Giuseppe Maglietta (12992976)

    Published 2024
    “…Level change for Mental Disorders significantly decreased during school closure (HRR 0.50, 95%CI 0.30–0.82) but increased during mitigation measures by 28% (HRR 1.28, 95%CI 0.98–1.69).…”
  4. 14604

    Data_Sheet_1_Effects of COVID-19-targeted non-pharmaceutical interventions on pediatric hospital admissions in North Italian hospitals, 2017 to 2022: a quasi-experimental study int... by Giuseppe Maglietta (12992976)

    Published 2024
    “…Level change for Mental Disorders significantly decreased during school closure (HRR 0.50, 95%CI 0.30–0.82) but increased during mitigation measures by 28% (HRR 1.28, 95%CI 0.98–1.69).…”
  5. 14605
  6. 14606

    Effect of Warmed Ropivacaine Versus Room Temperature Ropivacaine Performing Spinal Anesthesia on Recovery of Lower Limb Muscle Strength Following Total Knee or Hip Replacement: A P... by erfei zhang (21529940)

    Published 2025
    “…The primary outcomes which were the proportion of patients with operative limb muscle strength at 3.5 hours post-anesthesia not less than grade 4 was significantly increased 28.5% by warmed ropivacaine compared to room temperature ropivacaine and the time of operation limb achieving grade 5 muscle strength was significantly decreased in the Group W (3.70 [2.8, 5.0] hours) compared to the Group N (5.5 [3.7-7.0] hours). …”
  7. 14607
  8. 14608

    Data_Sheet_1_Comparison of Postnatal Growth Charts of Singleton Preterm and Term Infants Using World Health Organization Standards at 40–160 Weeks Postmenstrual Age: A Chinese Sing... by Li Zhang (8200)

    Published 2021
    “…The Z-scores for length/height, weight, and BMI of preterm infants relative to the WHO standards gradually decreased from 1.20, 1.13, and 0.74 at 40–44 weeks PMA to 0.67, 0.42, and 0.03 at 132–160 weeks PMA, respectively; Z-scores for HC of preterm infants rapidly decreased from 0.73 to 0.29 at 40–50 weeks PMA, and then fluctuated in the range of 0.08–0.23 at 50–160 weeks PMA. …”
  9. 14609

    Transfection efficiency corrected <sup>3</sup>H-gemcitabine uptake in HEK293 (A), AsPC-1 (B), and MIA PaCa-2 (C) cells with or without transfection of hCNT3 cDNA. by Robert J. Paproski (282968)

    Published 2013
    “…Uptake values were corrected for transfection efficiency as described in the <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0056423#s2" target="_blank">methods</a> section. …”
  10. 14610

    Data_Sheet_1_Diabetes-specific formula with standard of care improves glycemic control, body composition, and cardiometabolic risk factors in overweight and obese adults with type... by Siew Ling Tey (7480985)

    Published 2024
    “…This randomized controlled trial investigated the effects of a diabetes-specific formula (DSF) on glycemic control and cardiometabolic risk factors in adults with type 2 diabetes (T2D).…”
  11. 14611

    DataSheet1_A randomized, open-label, parallel pilot study investigating metabolic product kinetics of the novel ketone ester, bis-hexanoyl (R)-1,3-butanediol, over one week of inge... by Eunice Mah (5918042)

    Published 2023
    “…</p><p>Methods: We undertook a randomized, parallel, open-label study in healthy adults (n = 33) to elucidate blood BHB, HEX and BDO concentrations for 8 h following consumption of three different serving sizes (SS) of BH-BD (12.5, 25 and 50 g/day) before (Day 0) and after 7 days of daily BH-BD consumption (Day 7).…”
  12. 14612

    Data Sheet 1_Global, regional, and national burden of interstitial lung disease in middle-aged and older adults from 1990 to 2021 with projections to 2050: a systematic analysis of... by Long Chen (315739)

    Published 2025
    “…Background<p>Interstitial lung disease (ILD) constitutes a significant global health challenge. However, existing epidemiological studies predominantly focus on worldwide and regional distribution patterns, while a substantial knowledge gap persists regarding the epidemiological characteristics of ILD among middle-aged and older adults (50–74 years). …”
  13. 14613
  14. 14614

    High-throughput screening and <i>in vitro</i> evaluation of CSB-0914; a novel small molecule NF-κB inhibitor attenuating inflammatory responses through NF-κB, Nrf2 and HO-1 cross-t... by Mesfer Al Shahrani (13774273)

    Published 2023
    “…The compound demonstrated significant efficacy in reducing basophil activation assay induced by FcεRI receptors, with an IC50 value of 98.41 nM.. A dose dependent decrease in neutrophil migration and elastase were observed when treated with CSB- 0914. …”
  15. 14615

    DataSheet_1_Multi-b-values-fitting readout-segmentation of long variable echo-trains diffusion-weighted imaging (RESOLVE DWI) in evaluation of disease activity and curative effect... by Xianyuan Chen (16482096)

    Published 2023
    “…</p>Conclusion<p>Multi-b-values-fitting (b=50,500,700s/mm<sup>2</sup>) RESOLVE DWI has a certain advantage in evaluating disease activity of axSpA. …”
  16. 14616
  17. 14617
  18. 14618
  19. 14619
  20. 14620

    <i>skn-1b</i> is not required for WT or <i>daf-2</i> longevity A-F) Survival of WT and <i>skn-1b</i> mutants in the absence and presence of <i>daf-2</i> mutation. by Nikolaos Tataridas-Pallas (10231350)

    Published 2021
    “…We conclude that <i>skn-1b</i> does not contribute to <i>daf-2</i> longevity. In a total of 15 trials (13 on OP50, 2 on HT115) bacteria we observed a slight decrease in <i>skn-1b</i> longevity compared to WT in 4 trials (<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1009358#pgen.1009358.s004" target="_blank">S4</a> and <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1009358#pgen.1009358.s005" target="_blank">S5</a> Tables). …”